Table 3.
Representative clinical trials of FGFR inhibitors for solid tumors
| Inhibitors | Inhibitor types |
ClinicalTrials.gov ID |
Phase | Conditions or diseases | Status |
|---|---|---|---|---|---|
| Lucitanib | Multi-kinase FGFR inhibitor (FGFR, VEGFR, PDGFR) | NCT01283945 | 1/2 | Solid Tumors | Completed |
| 3D185 | Multi-kinase FGFR inhibitor (FGFR, CSF1R) | NCT04221204 | 1 | Solid tumors | Recruiting |
| Sulfatinib | Multi-kinase FGFR inhibitor (FGFR, VEGFR, CSF1R) | NCT02133157 | 1 | Tumors | Completed |
| MAX-40279–01 | Multi-kinase FGFR inhibitor (FGFR, Flt3) | NCT05369286 | 1 | Solid tumors | Recruiting |
| TT-00420 | Multi-kinase FGFR inhibitor (FGFR, VEGFR, Aurora Kinases, JAK) | NCT04742959 | 1/2 | Advanced solid tumors | Recruiting |
| Regorafenib | Multi-kinase FGFR inhibitor (RET, VEGFR, c-KIT, PDGFR, FGFR, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, SAPK2, PTK5, Abl) | NCT04116541 | 2 | Malignant solid tumors | Recruiting |
| Erdafitinib | Selective FGFR inhibitor | NCT04083976 | 2 | Advanced solid tumors | Recruiting |
| HMPL-453 | Selective FGFR inhibitor | NCT05173142 | 1/2 | Solid tumors | Recruiting |
| Pemigatinib | Selective FGFR inhibitor | NCT04591431 | 2 | Progressive diseases of breast cancer, metastatic gastrointestinal tumors, non-small cell lung cancer or others | Recruiting |
| Futibatinib | Selective FGFR inhibitor | NCT04189445 | 2 | Advanced or metastatic solid tumors | Recruiting |
| KIN-3248 | Selective FGFR inhibitor | NCT05242822 | 1 | Solid tumors | Recruiting |
| Infigratinib | Selective FGFR inhibitor | NCT04233567 | 2 | Advanced or metastatic solid tumors | Recruiting |
| ASP-5878 | Selective FGFR inhibitor | NCT02038673 | 1 | Solid tumors | Completed |
| LY2874455 | Selective FGFR inhibitor | NCT01212107 | 1 | Advanced cancer | Completed |
| CPL304110 | Selective FGFR inhibitor | NCT04149691 | 1 | Advanced solid malignancies | Recruiting |
| E7090 | Selective FGFR inhibitor | NCT04962867 | 2 | Advanced or recurrent solid tumors | Recruiting |
| Bemarituzumab | Monoclonal antibody | NCT05325866 | 1 | Solid tumors | Not yet recruiting |
| BAY1179470 | Monoclonal antibody | NCT01881217 | 1 | Advanced, refractory solid tumors | Completed |
| LY3076226 | Antibody-drug conjugate | NCT02529553 | 1 | Advanced or metastatic cancer | Completed |
| GSK3052230 | FGF ligand trap | NCT01868022 | 1 | Neoplasms | Completed |
| EVER4010001 + Pembrolizuman | EVER4010001 (FGFR4 inhibitor), Pembrolizuman (PD-1 inhibitor) | NCT04699643 | 1/2 | Advanced solid tumors | Recruiting |
| Infigratinib + BYL719 | Infigratinib (selective FGFR inhibitor), BYL719 (PIK3K inhibitor) | NCT01928459 | 1 | Advanced or metastatic solid tumors | Completed |
| Nintedanib + Pembrolizumab | Nintedanib (FGFR, VEGFR, PDGFR inhibitor), Pembrolizumab (PD-1 inhibitor) | NCT02856425 | 1 | Advanced solid tumors | Recruiting |
| Surufatinib + Gemcitabine | Surufatinib (FGFR, VEGFR, CSF1R inhibitor), Gemcitabine (Chemotherapy) | NCT05093322 | 1/2 | Recurrent or refractory solid tumors or lymphoma | Recruiting |
| Nintedanib + Everolimus | Nintedanib (FGFR, VEGFR, PDGFR inhibitor), Everolimus (mTOR inhibitor) | NCT01349296 | 1 | Solid tumors | Completed |